5,869,091 Shares in CAMP4 Therapeutics Corporation $CAMP Bought by 5AM Venture Management LLC

5AM Venture Management LLC bought a new position in shares of CAMP4 Therapeutics Corporation (NASDAQ:CAMP - Free Report) during the second quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund bought 5,869,091 shares of the Wireless communications provider's stock, valued at approximately $25,647,928. CAMP4 Therapeutics comprises approximately 0.0% of 5AM Venture Management LLC's holdings, making the stock its 5th largest position. 5AM Venture Management LLC owned 9.35% of CAMP4 Therapeutics as of its most recent filing with the Securities & Exchange Commission.

A number of other institutional investors have also added to or reduced their stakes in CAMP. Vivo Capital LLC acquired a new position in CAMP4 Therapeutics during the third quarter worth $11,765,000. Balyasny Asset Management L.P. acquired a new position in CAMP4 Therapeutics during the fourth quarter worth $14,938,000. Janus Henderson Group PLC increased its holdings in CAMP4 Therapeutics by 35.9% during the fourth quarter. Janus Henderson Group PLC now owns 6,307,636 shares of the Wireless communications provider's stock worth $38,807,000 after buying an additional 1,666,666 shares during the last quarter. BlackRock Inc. acquired a new position in CAMP4 Therapeutics during the second quarter worth $7,185,000. Finally, SummitTX Capital L.P. acquired a new position in CAMP4 Therapeutics during the first quarter worth $1,497,000.

CAMP4 Therapeutics Price Performance

NASDAQ:CAMP opened at $4.15 on Friday. CAMP4 Therapeutics Corporation has a one year low of $1.41 and a one year high of $7.75. The company has a market cap of $260.41 million, a P/E ratio of -1.79 and a beta of 0.22. The firm's fifty day moving average price is $4.13 and its two-hundred day moving average price is $4.36.

CAMP4 Therapeutics (NASDAQ:CAMP - Get Free Report) last released its quarterly earnings data on Thursday, August 13th. The Wireless communications provider reported ($0.58) EPS for the quarter, missing the consensus estimate of ($0.24) by ($0.34). CAMP4 Therapeutics had a negative net margin of 2,543.74% and a negative return on equity of 252.79%. The company had revenue of $1.78 million during the quarter. As a group, equities research analysts expect that CAMP4 Therapeutics Corporation will post -0.57 earnings per share for the current year.

Insider Buying and Selling at CAMP4 Therapeutics

In other CAMP4 Therapeutics news, Director Andrew J. Schwab sold 114,700 shares of the company's stock in a transaction on Thursday, August 20th. The shares were sold at an average price of $4.54, for a total value of $520,738.00. Following the transaction, the director directly owned 2,465,298 shares in the company, valued at $11,192,452.92. The trade was a 4.45% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. Also, Director Richard A. Young acquired 16,378 shares of the firm's stock in a transaction on Monday, August 3rd. The stock was bought at an average price of $1.65 per share, for a total transaction of $27,023.70. Following the completion of the acquisition, the director owned 186,388 shares of the company's stock, valued at approximately $307,540.20. The trade was a 9.63% increase in their ownership of the stock. Additional details regarding this purchase are available in the official SEC disclosure. Over the last quarter, insiders acquired 36,031 shares of company stock worth $59,451 and sold 193,613 shares worth $888,037. 21.69% of the stock is owned by insiders.

Analyst Upgrades and Downgrades

A number of equities analysts recently weighed in on the stock. Piper Sandler restated an "overweight" rating and set a $15.00 target price (up from $12.00) on shares of CAMP4 Therapeutics in a report on Friday, August 14th. Zacks Research upgraded shares of CAMP4 Therapeutics from a "strong sell" rating to a "hold" rating in a report on Monday, August 17th. Weiss Ratings upgraded shares of CAMP4 Therapeutics from a "sell (e+)" rating to a "sell (d-)" rating in a report on Friday, August 14th. Chardan Capital set a $6.50 target price on shares of CAMP4 Therapeutics and gave the stock a "buy" rating in a report on Wednesday, June 10th. Finally, JPMorgan Chase & Co. upgraded shares of CAMP4 Therapeutics from a "neutral" rating to an "overweight" rating and boosted their target price for the stock from $5.00 to $9.00 in a report on Tuesday, June 16th. Seven investment analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat.com, CAMP4 Therapeutics currently has a consensus rating of "Moderate Buy" and an average price target of $9.56.

CAMP4 Therapeutics Profile

CalAmp Corp., a connected intelligence company, provides leverages a data-driven solutions ecosystem to people and organizations in the United States, Europe, the Middle East, Africa, Latin America, the Asia-Pacific, and internationally. The company operates in two segments, Software & Subscription Services and Telematics Products. It provides CalAmp Telematics Cloud platform, such as cloud-based application enablement and telematics service platforms that facilitate integration of its own applications, as well as those of third parties, through open application programming interfaces; and software as a service application, as well as provides tracking and monitoring services within fleet management, supply chain integrity, and international vehicle location.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source